Pfisterer M, Teetzmann A, Vetter S, Baeßler J, Schreckenberger L, Zaiser J, Stenger M, Bach P. CBD attenuates amygdala response to negative emotional stimuli in individuals with alcohol use disorder - a randomized controlled trial. Psychopharmacology (Berl). 2025 Aug 29. [Epub ahead of print]
Pfisterer M, Zimmermann S, Zaiser J, Gerhardt S, Vollstädt-Klein S, Kiefer F, Bach P. Biomarkers in alcohol use disorder - the promise and pitfalls of neuroimaging drug cue reactivity. Biomarkers in neuropsychiatry. 2025 12:100119.
Vetter S, Schnabel S, Reichl M, Sirignano L, Grinevich V, Koopmann A, Spanagel R, Kiefer F, Sommer WH, Bach P. Intranasal oxytocin blunts amygdala response to negative affective stimuli in males and females with alcohol use disorder: a randomized controlled cross-over trial. Psychopharmacology (Berl). 2025 242(9):1995-2007. Epub 2025 Mar 31.
Vetter S, Weinberg J, Thomas BC, Kirchner M, Thalmann P, Klose C, Pfisterer M, Kölsch T, Oesterle S, Vollstädt-Klein S, Koopmann A, Lenz B, Kiefer F, Link T, Bach P. Investigation of the combined effects of cannabidiol plus naltrexone on alcohol craving in alcohol dependence: study protocol of a phase II randomised, double-blind, placebo-controlled, parallel-group trial - ICONICplus Trial. BMJ Open. 2025 15(8):e106348.
Zaiser J, Hoffmann S, Zimmermann S, Gessner T, Deck M, Bekier N, Abel M, Radler P, Langejürgen J, Lenz B, Vollstädt-Klein S, Stallkamp J, Kirschbaum C, Kiefer F, Bach P. Individual stress reactivity predicts alcohol craving and alcohol consumption in alcohol use disorder in experimental and real-life settings. Transl Psychiatry. 2025 15(1):226.
Zimmermann S, Teetzmann A, Baeßler J, Schreckenberger L, Zaiser J, Pfisterer M, Stenger M, Bach P. Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial. Mol Psychiatry. 2025 30(6):2612-2619. Epub 2024 Dec 12.